Ultragenyx Pharmaceutical (RARE) Operating Income Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.66% |
| Dec 31, 2025 | -3.35% |
| Sep 30, 2025 | -27.70% |
| Jun 30, 2025 | -11.34% |
| Mar 31, 2025 | -3.45% |
| Dec 31, 2024 | -5.30% |
| Sep 30, 2024 | -2.26% |
| Jun 30, 2024 | -0.68% |
| Mar 31, 2024 | -10.76% |
| Dec 31, 2023 | -6.17% |
| Sep 30, 2023 | -10.11% |
| Jun 30, 2023 | -9.29% |
| Mar 31, 2023 | -9.82% |
| Dec 31, 2022 | -8.50% |
| Sep 30, 2022 | -21.87% |
| Jun 30, 2022 | -12.54% |
| Mar 31, 2022 | -14.33% |
| Dec 31, 2021 | -7.77% |
| Sep 30, 2021 | -6.43% |
| Jun 30, 2021 | -7.35% |
| Mar 31, 2021 | -14.72% |
| Dec 31, 2020 | -11.34% |
| Sep 30, 2020 | -4.73% |
| Jun 30, 2020 | -15.91% |
| Mar 31, 2020 | -41.20% |
| Dec 31, 2019 | -41.01% |
| Sep 30, 2019 | -49.44% |
| Jun 30, 2019 | -52.45% |
| Mar 31, 2019 | -57.19% |
| Dec 31, 2018 | -56.82% |
| Sep 30, 2018 | -63.13% |
| Jun 30, 2018 | -63.00% |
| Mar 31, 2018 | -70.24% |